Mobia Medical (NASDAQ:MOBI) Director Purchases $203,417.10 in Stock

Mobia Medical, Inc. (NASDAQ:MOBI) Director Casey Tansey bought 17,166 shares of Mobia Medical stock in a transaction that occurred on Monday, August 17th. The stock was purchased at an average price of $11.85 per share, with a total value of $203,417.10. Following the purchase, the director directly owned 301,891 shares in the company, valued at $3,577,408.35. The trade was a 6.03% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Mobia Medical Stock Performance

Mobia Medical stock opened at $11.42 on Thursday. The company has a current ratio of 13.28, a quick ratio of 12.80 and a debt-to-equity ratio of 0.04. The company’s 50-day moving average price is $12.38. The stock has a market cap of $380.17 million and a P/E ratio of -0.59. Mobia Medical, Inc. has a fifty-two week low of $10.19 and a fifty-two week high of $15.29.

Mobia Medical (NASDAQ:MOBI) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.27). The firm had revenue of $13.51 million during the quarter. The firm’s revenue was up 102.4% on a year-over-year basis. As a group, analysts predict that Mobia Medical, Inc. will post -2.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on MOBI. The Goldman Sachs Group assumed coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They set a “buy” rating and a $31.00 price objective for the company. BTIG Research reiterated a “buy” rating and issued a $19.00 price objective on shares of Mobia Medical in a research note on Wednesday, August 12th. JPMorgan Chase & Co. raised their target price on shares of Mobia Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Wolfe Research began coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They issued an “outperform” rating on the stock. Finally, Wall Street Zen raised Mobia Medical from a “sell” rating to a “hold” rating in a research report on Sunday, June 14th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.75.

About Mobia Medical

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.